Biologics in Rheumatology 2012
نویسنده
چکیده
The term biologics have been used as a collective term for biological therapies. Therapeutic agents with biologic properties, including monoclonal antibodies and soluble cytokine receptors have been in use against rheumatic diseases for some time now. Treatment of rheumatic diseases has undergone a remarkable change over the last 10 years. This can be credited to an increased understanding of the immune system and the mechanisms and causes of rheumatic diseases which has enabled us to treat the underlying cause aggressively and early. The use of biologics has become essential along with DMARDs in treatment of autoimmune diseases.
منابع مشابه
Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
SIR, We thank Dr Von Vollenhoven for his interest in our paper. The questions [1] he raises about our article that examined the cost–effectiveness of biologics using the British Society for Rheumatology Biologics Registry (BSRBR) [2] provide an excellent opportunity to describe why decision modelling should be used in calculating a majority of cost–effectiveness ratios. We refer to an article b...
متن کاملDetection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.
OBJECTIVES A high incidence of pancreatic cancer (PCa) in patients exposed to was observed in the German biologics register. To evaluate this possible safety signal, a concerted analysis with the national biologics registers in the UK and Sweden was performed. METHODS Patients with enrolled in the British Society of Rheumatology Biologics Register (BSRBR), the Swedish Rheumatology Register (S...
متن کاملThe 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics.
The last British Society of Rheumatology (BSR) guidelines for the treatment of PsA were published in 2005 when antiTNF therapy was not widely available. At that time only one of the anti-TNF therapies was licensed for the treatment of PsA. Since then, their use in PsA has become more widespread, with multiple anti-TNF drugs licensed for the treatment of PsA and approved for therapy by the Natio...
متن کاملManagement of rheumatoid arthritis: the 2012 perspective.
Management of rheumatoid arthritis (RA) has improved over the last 10 years. These changes have been monitored in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) observational cohort, and clinical remission has become a realistic goal. However, we should recognize that the ultimate goal of treatment is to improve long-term outcomes. These improvements have been achieved not only by ...
متن کاملPres-FINAL-2009: Pediatric rheumatology practitioners experience with biologics in juvenile dermatomyositis: survey results
Introduction Biologic therapy is increasingly prescribed in rheumatologic disorders. Juvenile dermatomyositis (JDM), the most common inflammatory myopathy in children, can be challenging to manage in a subset of patients. There are multiple reports of cytokine involvement in JDM. There is a paucity of information regarding the use of biologics for JDM among pediatric rheumatology practitioners,...
متن کامل